To provide recommendations for pharmacologic treatment options for weight management in nonpregnant adult patients with obesity or selected patients with overweight and weight-related comorbidities.
Key Findings:
Semaglutide and tirzepatide are recommended as first-line treatments for obesity based on moderate-certainty evidence, while phentermine-topiramate, liraglutide, and naltrexone-bupropion are recommended as second, third, and fourth-line treatments, respectively, based on low-certainty evidence.
Interpretation:
The ACP concluded that semaglutide and tirzepatide provide the greatest net benefit among evaluated treatments for obesity management.
Limitations:
Evidence for patients with overweight was limited, particularly regarding pharmacologic treatments, which may affect treatment decisions.
Conclusion:
Clinicians and patients should discuss various factors, including potential side effects and treatment goals, when initiating or switching weight-management medications.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
